Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-06-24

Clinical Trial Update: SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating SU5416 for persistent or recurrent cervical cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SU5416 (semaxanib)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Cervical Cancer | Phase 2 | Status: COMPLETED